Shanghai Haohai Biological Technology Co (SHSE:688366) Other Current Payables: ¥306 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:688366 Shanghai Haohai Biological Technology Co Ltd SHSE:688366
73 GF Score
Price ¥31.98
GF Value ¥47.64
Valuation Significantly Undervalued
! 5 Warning Signs
View Full Analysis

What is Shanghai Haohai Biological Technology Co Other Current Payables?

Shanghai Haohai Biological Technology Co SHSE:688366 -3.96% 73 Other Current Payables is ¥306 Mil as of Mar. 2026. GuruFocus rates SHSE:688366 with a GF Score™ of 73/100 and a GF Value™ of ¥47.64 (Significantly Undervalued). The stock has 5 warning signs investors should review.

Shanghai Haohai Biological Technology Co's Other Current Payables for the quarter that ended in Mar. 2026 was ¥306 Mil.

Shanghai Haohai Biological Technology Co's quarterly Other Current Payables declined from Sep. 2025 (¥455 Mil) to Dec. 2025 (¥197 Mil) but then increased from Dec. 2025 (¥197 Mil) to Mar. 2026 (¥306 Mil).

Shanghai Haohai Biological Technology Co's annual Other Current Payables increased from Dec. 2023 (¥208 Mil) to Dec. 2024 (¥209 Mil) but then declined from Dec. 2024 (¥209 Mil) to Dec. 2025 (¥197 Mil).

Shanghai Haohai Biological Technology Co Other Current Payables Related Terms

Shanghai Haohai Biological Technology Co Other Current Payables Historical Data

* Premium members only.

The historical data trend for Shanghai Haohai Biological Technology Co's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shanghai Haohai Biological Technology Co Other Current Payables Chart

Shanghai Haohai Biological Technology Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Payables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 170.52 192.31 208.28 209.17 196.75

Shanghai Haohai Biological Technology Co Quarterly Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Jun25 Sep25 Dec25 Mar26
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 209.17 247.58 455.33 196.75 306.08
SHSE:688366
73GF Score
Shanghai Haohai Biological Technology Co Ltd SHSE:688366
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shanghai Haohai Biological Technology Co Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of ¥306 Mil mean?
Shanghai Haohai Biological Technology Co (SHSE:688366) has a Other Current Payables of ¥306 Mil as of Mar. 2026. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Shanghai Haohai Biological Technology Co and its competitors.
Is Shanghai Haohai Biological Technology Co's Other Current Payables too high?
Shanghai Haohai Biological Technology Co's current Other Current Payables is ¥306 Mil. Overall, Shanghai Haohai Biological Technology Co has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Haohai Biological Technology Co's Other Current Payables compare to VRTX and REGN?
Shanghai Haohai Biological Technology Co's Other Current Payables of ¥306 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Biotechnology company?
A good Other Current Payables depends on the Biotechnology industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Shanghai Haohai Biological Technology Co and its competitors. Shanghai Haohai Biological Technology Co's current Other Current Payables is ¥306 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Haohai Biological Technology Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Haohai Biological Technology Co (SHSE:688366) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥47.64, compared to a current price of ¥31.98 — trading 32.9% below its estimated fair value. The current Other Current Payables is ¥306 Mil. Shanghai Haohai Biological Technology Co's overall GF Score™ is 73/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For Shanghai Haohai Biological Technology Co (SHSE:688366), the current Other Current Payables is ¥306 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shanghai Haohai Biological Technology Co (SHSE:688366) Overvalued in 2026?

Based on GuruFocus' analysis, Shanghai Haohai Biological Technology Co stock appears to be undervalued. The current stock price of ¥31.98 is trading 32.9% below its estimated GF Value™ of ¥47.64. GuruFocus considers Shanghai Haohai Biological Technology Co to be Significantly Undervalued.

Key valuation signals for SHSE:688366:

  • Other Current Payables: ¥306 Mil
  • GF Value™: ¥47.64 vs. price of ¥31.98 (32.9% below fair value)
  • GF Score™: 73/100 with 5 warning signs

No single metric tells the full story. See the SHSE:688366 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Shanghai Haohai Biological Technology Co Business Description

Other Exchanges 06826:Hong Kong5HB:Germany
Address No. 1386 Hongqiao Road, 23rd Floor, WenGuang Plaza, Changning District, Shanghai, CHN
Shanghai Haohai Biological Technology Co Ltd is engaged in the manufacturing and sale of biologicals, medical hyaluronate, and ophthalmology products. The Company's operating activities are related to a single operating segment, which is the manufacture and sale of biologicals, medical hyaluronate, and intraocular lenses, research and development of biological engineering and pharmaceutical products, and the provision of related services. Its products are categorized into four types, comprising ophthalmology, medical aesthetics, orthopedics, and anti-adhesion. Geographically, it has operations in Mainland China, which is the key revenue driver, the United States, the United Kingdom, and other countries.
73GF Score

Get the complete analysis for SHSE:688366

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥31.98
Price
¥47.64
GF Value